Open source traffic analysis

ABA Home
Patent Law

Drug-Price Law Overturned

Posted Aug 3, 2007, 09:28 am CDT
By Debra Cassens Weiss

An appeals court has struck down a Washington, D.C., law barring drug companies from charging excessive prices for prescription drugs.

The D.C. law didn’t define excessive pricing. But it said a prima facie case could be established if the whosesale price of a patented drug was more than 30 percent higher than its comparable price in Canada or other high-income countries.

The U.S. Court of Appeals for the Federal Circuit ruled in an opinion (PDF) signed Wednesday that the D.C. law is pre-empted by federal patent law, the Washington Post reports.

The court noted the District’s argument that drug companies use market power to charge excessive prices for patented drugs.

"This may be a worthy undertaking on the part of the District government, but it is contrary to the goals established by Congress in the patent laws," the panel wrote. The District’s law is “in effect diminishing the reward to patentees in order to provide greater benefit to District drug consumers.”

E-Mail This Story


(Separate multiple addresses with a comma.)




Share This Story

URL to share: http://www.abajournal.com/news/drug_price_law_overturned/

Title: Drug-Price Law Overturned


Comments

    Be the first to comment.


Commenting has expired on this post.


Subscribe

Get the ABA Journal the way you want it — in print, online, by e-mail — and when you want it — monthly, weekly, daily or as news breaks.





Are you an ABA Member? Read This First

Subscribe via RSS
Subscribe to the mobile edition
Subscribe to the monthly magazine


Return to top